Fulgent Genetics Statistics
Share Statistics
Fulgent Genetics has 30.87M
shares outstanding. The number of shares has increased by 3.15%
in one year.
| Shares Outstanding | 30.87M |
| Shares Change (YoY) | 3.15% |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | 56.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 1.76M, so 5.71% of the outstanding
shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 5.71% |
| Short % of Float | 10.4% |
| Short Ratio (days to cover) | 4.14 |
Valuation Ratios
The PE ratio is -13.08 and the forward
PE ratio is -27.6.
Fulgent Genetics's PEG ratio is
0.17.
| PE Ratio | -13.08 |
| Forward PE | -27.6 |
| PS Ratio | 1.97 |
| Forward PS | 1.4 |
| PB Ratio | 0.49 |
| P/FCF Ratio | -29 |
| PEG Ratio | 0.17 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Fulgent Genetics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.85,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.85 |
| Quick Ratio | 4.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.44 |
| Interest Coverage | -434.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $215,894.9 |
| Profits Per Employee | $-32,527.04 |
| Employee Count | 1,313 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8.14M |
| Effective Tax Rate | 15.66% |
Stock Price Statistics
The stock price has increased by -18.69% in the
last 52 weeks. The beta is 1.37, so Fulgent Genetics's
price volatility has been higher than the market average.
| Beta | 1.37 |
| 52-Week Price Change | -18.69% |
| 50-Day Moving Average | 17.32 |
| 200-Day Moving Average | 19.48 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 467,345 |
Income Statement
In the last 12 months, Fulgent Genetics had revenue of 283.47M
and earned -42.71M
in profits. Earnings per share was -1.41.
| Revenue | 283.47M |
| Gross Profit | 107.22M |
| Operating Income | -73.92M |
| Net Income | -42.71M |
| EBITDA | -48.99M |
| EBIT | -73.92M |
| Earnings Per Share (EPS) | -1.41 |
Full Income StatementBalance Sheet
The company has 55.14M in cash and 8.47M in
debt, giving a net cash position of 46.68M.
| Cash & Cash Equivalents | 55.14M |
| Total Debt | 8.47M |
| Net Cash | 46.68M |
| Retained Earnings | 590.47M |
| Total Assets | 1.22B |
| Working Capital | 280.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 21.06M
and capital expenditures -40.31M, giving a free cash flow of -19.25M.
| Operating Cash Flow | 21.06M |
| Capital Expenditures | -40.31M |
| Free Cash Flow | -19.25M |
| FCF Per Share | -0.64 |
Full Cash Flow StatementMargins
Gross margin is 37.82%, with operating and profit margins of -26.08% and -15.07%.
| Gross Margin | 37.82% |
| Operating Margin | -26.08% |
| Pretax Margin | -18.33% |
| Profit Margin | -15.07% |
| EBITDA Margin | -17.28% |
| EBIT Margin | -26.08% |
| FCF Margin | -6.79% |
